0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > CXCL13

CXCL13

Brief Information

Name:C-X-C motif chemokine 13
Target Synonym:BCA-1,B cell-attracting chemokine 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
CX3-H1249 Human Human CXCL13 / BCA-1 Protein, His Tag
CX3-H1249-structure
CX3-H1249-sds
ACRO Quality

Synonym Name

C-X-C motif chemokine 13,Angie,B cell-attracting chemokine 1,BCA-1,B lymphocyte chemoattractant,CXC chemokine BLC,Small-inducible cytokine B13,CXCL13,BCA1,BLC,SCYB13

Background

CXCL13, originally known as BLC (B-lymphocyte chemoattractant) or BCA-1 (B cell-attracting chemokine 1), is a homeostatic chemokine. It is constitutively secreted by stromal cells in B-cell areas of secondary lymphoid tissues (follicles), such as spleen, lymph nodes, tonsils, and Peyer's patches. CXCL13 plays a key role in orchestrating cell migration within spatially distinct regions of the secondary lymphoid organs. It strongly attracts B lymphocytes while promoting migration of only small numbers of T cells and macrophages. CXCL13 exerts its functions through its receptor CXCR5, which initially, was isolated from Burkitt Lymphoma and therefore designated as Burkitt's lymphoma receptor 1 (BLR1).

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
KAND-145 KAND-145 Phase 1 Clinical Kancera Ovarian Neoplasms; Inflammation Details
KAND-145 KAND-145 Phase 1 Clinical Kancera Ovarian Neoplasms; Inflammation Details

This web search service is supported by Google Inc.

totop

Laisser un message